Skip to main content

Nicholson Nur's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Sep 19, 2023

Accession no.
0001127602-23-024445
Filed
Sep 19, 2023
Trade date
Sep 18, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $900.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Nicholson NurCIK 0001827317Officer (Chief Technical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 18, 2023Common StockMOption exerciseAcquired+9,719$29.76+$289,237.4473,634Direct
Sep 18, 2023Common StockSSaleDisposed−9,719$42.21−$410,238.9963,915Direct
Sep 18, 2023Common StockSSaleDisposed−10,631$46.15−$490,620.6553,284Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 18, 2023Common StockMOption exerciseDisposed−9,719$0.00$0115,281Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)